chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Itchy arm, then throughout the day has slowly grown into a lump. I've drawn a circle around it and it's gotten bigger. About some inches. Now not as itchy, more burning underneath sensation - definitely feels hot underneath. Whole arm hurts. I can feel the pain constantly and its a 2/3 in a 10 scale. Yesterday was my first day since vaccine that I did a heavy arm workout. I felt my left arm weaker as I was doing biceps but I pushed through.
Erythematous macular of cheeks, upper neck & back. Swollen eyelids, no SOB, mental status normal, child active, no fever.
Red raised bumps down torso and extremities. Patient denies itching, denies pain. Patient came to clinic 08:37AM. Patient was seen by provider. Ok'd to discharge. Patient to call with worsening symptoms. Dr. diagnosed patient with chicken pox.
developed whelps on his torso; start to itch; This case was reported by a consumer via call center representative and described the occurrence of welts in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, couple of months after receiving Shingrix and an unknown time after starting Cortison, the patient experienced welts and pruritus. The patient was treated with cortisone acetate (Cortison). On an unknown date, the outcome of the welts and pruritus were unknown.   It was unknown if the reporter considered the welts and pruritus to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix vaccine approximately two years ago and few months after receiving he developed whelps on his torso.  He went to the dermatologist and biopsies were performed.  The dermatologist did not feel that the whelps were related to the Shingrix vaccine.   The reporter described that he has remnants of the whelps on his torso.   When they start to itch he puts cortisone on them. The reporter unable to obtain additional details and reporter was not willing to continue the call.
After several days her arm felt itchy, looked in the mirror and had a rash around the site, just little red dots. The area got worse, she made an appointment for a dermatologist for the next day.  It doubled in size, and then doubled again and as an artist it was interesting.  Her husband researched the symptoms and said that it's COVID arm and it's usually typical in people in their 30's and 40's.   She went to the Dermatologist on 2/11/21 who said that it's at the site of the injection.  He told her to take Cortisone for that day, Clobetasol 0.5%.  She did that for the day, and he sent in a prescription to start the next day hydrocortisone 2.5% cream 2-3 days a day.  It got much worse.  Today it is a brownish area, fading, the redness has gone as well, itchy at times as well.   She does have pictures that she is willing to submit.
Started to get dizzy, weak and nervous around an hour an a half after shot.  Arm swelled at injection site, was warm and red. As the day went on started to feel sick with shivers,  fever, nausea and body aches. Very shaky and feverish in the middle of the night and woke up to the bed drenched with sweat. Was close to vomiting.  Recorded my temperature the next day. Highest recorded temp was 100.7. Slight loss of appetite over the course of 2-3 to 2-4.  Arm started itching 2-4 and is still itchy today 2-6, but nothing extreme. Arm still is hard, raised up, tender and warm around injection site. Felt pretty much back to normal upon waking on 2-5.
Sore arm; Fever; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm) and PYREXIA in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Sore arm) and PYREXIA. At the time of the report, PAIN IN EXTREMITY (Sore arm) and PYREXIA had resolved.            This case was linked to MOD-2021-030618.
Information was received on 03DEC2014 from a certified medical assistant who reported that two patients (see MARRS # 1412USA001870 for second patient) received improperly stored RECOMBIVAX HB 10/1.0 mcrg/ml (lot # K011239 expiration 11JUN2016) which was exposed to 48 degrees Fahrenheit for 108 hours on 01DEC2014. No adverse effects were reported. No further information was provided. Additional information is expected.
Information has been received from a consumer who on approximately 21-JAN-2008 was vaccinated with a third dose of GARDASIL. The consumer was breast feeding her 1 year old infant. On approximately 26-JAN-2008, "in the last couple of days", the infant developed a rash on it's cheek. At the time of reporting the infant had not recovered. Additional information has been requested.
Noted a rash diffuse papular and itching, nothing that appeared like wheals or hives.  Started about 24 hours after vaccine, has been taking diphenhydramine at night only.  Rash today, day 4, appears minimal and resolving.
Discharge Summary MD (Physician) ? ? Hospitalist Physician Discharge Summary   Patient ID: 74 y.o.    Admit Date:  7/5/2022   Discharge Date: 7/9/22   Principal Dx/ Final Dx: Bacteremia due to Klebsiella pneumoniae   Relevant Inpt Dx: Principal Problem:   Bacteremia due to Klebsiella pneumoniae Active Problems:   Type 2 diabetes mellitus, with long-term current use of insulin   Fever   Benign essential HTN   H/O Whipple procedure   Abnormal CT of the abdomen   Sepsis   AKI (acute kidney injury)   COVID-19 virus infection       HPI:   Hospital Course:   This 74 year old man was admitted with klebsiella bacteremia.  He has pancreatic cancer and had past whipple.  He presented with chills.  Blood cultures grew klebsiella.  He was treated with iv antibiotics and did well.  Repeat cultures show clearing of blood.  He will complete antibiotics orally based on sensitivities.     CT did show abnormalities felt due to surgery.  There was also concern for recurrence of malignancy.  He has talked with his surgeon by phone and will follow up with facility in near future.     He did test positive for covid but did not require any treatment  Notes    Component Ref Range & Units 01:10  T BILIRUBIN 0.2 - 1.0 mg/dL 2.8 High   D BILIRUBIN 0.0 - 0.2 mg/dL 1.7 High   Albumin 3.2 - 5.0 g/dL 2.6 Low   ALT (SGPT) 10 - 60 [iU]/L 28  AST 10 - 42 [iU]/L 24  ALP 42 - 121 [iU]/L 330 High   PROTEIN TOTAL 6.1 - 7.8 g/dL 5.0 Low          MPRESSION:  From CT scan 1.  Postoperative changes from Whipple procedure secondary to pancreatic carcinoma.  There has been interval development of marked intra hepatic biliary ductal dilation extending to the main left and right intrahepatic ducts near the level of the of the choledochojejunostomy.  Although the there is relative density change in the porta hepatis this may simply be secondary to partial volume averaging with the adjacent bowel loop in the porta hepatis.  No more definitive masses identified.  Differential would remain benign stricture related to the choledochojejunostomy versus malignant obstruction.  Would consider follow-up MRI of the abdomen without and with IV contrast and MRCP for further evaluation. 2.  Multiple new small non calcified nodules in the lingula and left lower lobe suspicious for metastatic disease in this patient with history of pancreatic carcinoma.       Consults:   IP CONSULT TO HOSPITALIST       Disposition:  home   Discharge Condition:  fair
rash from head to toe; This is a spontaneous report. A non-contactable other healthcare professional reported that a female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number was not reported, Expiration Date: 22Feb2021), via an unspecified route of administration on 22Feb2021 as dose 1, single for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. On an unspecified date, the patient experienced rash from head to toe with outcome of unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
low grade fever, aches, chills, mild headache - got worse after I got up this morning
Day 7 post MMR vax pt ran fever x 3days w/rash over entire body fussy until Sunday or day 12 w/inc rash; on exam 20JAN92 petechiae found around neck in throat;
pain in shoulder--arm pit hurts--upper arm hurts--went to md--md said "frozen shoulder"--md did exrays
At approximately 0200 on 9/1/2021 I woke up with the urge to vomit. As I was walking to my bathroom I became very dizzy, weak, cold and tingly. The next thing I knew, I was laying on the floor in my hallway. I believe I had vasovagal syncope, or something in relation to the vaccine that caused me to pass out.
PATIENT COMPLAINS OF "FUNNY" DRIPPING FEELING IN HER THROAT. 1 TABLET DIPHENHYDRAMINE 25MG, PO, GIVEN AT 12:00PM. PATIENT MONITORED, VITALS EVERY 5 MINUTES, PATIENT REPORTS FEELING BETTER. PATIENT LEFT CLINIC AT 12:30PM, ALERT AND ORIENTED X3, AND WALKING.
Information has been received from a 47 year old white female RN with an allergy to cephalosporins who on approximately 30Jan03 was vaccination with a dose of varicella virus vaccine live. There was no illness at the time of vaccination. On approximately 20Feb03, three weeks later, the pt developed break through chickenpox. The reporter indicated that it was a light case of the chicken pox, although she did note that she has not seen the pt and is unable to describe the pt in more detail. Unspecified medical attention was sought. Intervention was unknown. No diagnostic tests or laboratory data were reported. Follow up information received from a consumer indicated that on 10Feb2003 in the AM she developed a fever for 24 hours and then broke out with pox totaling about 10 or 15. She reported that she was better in 5 days, and was noted to have recovered. This is an amended report. The primary reporter was changed from the consumer to a registered nurse. The adverse event onset time of 08:00 was deleted. No further information is expected. This is a corrected report as amended.
No adverse Event; Patient got vaccinated after BUD; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient got vaccinated after BUD) and NO ADVERSE EVENT (No adverse Event) in a 74-year-old patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 084J21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 19-Apr-2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 19-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient got vaccinated after BUD). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse Event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient got vaccinated after BUD) and NO ADVERSE EVENT (No adverse Event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse Event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Patient got vaccinated after BUD).    No concomitant medications were reported.  It was reported that, the patient received vaccine after the beyond use-by date.  No treatment medications were reported.
after the third dose, she states that her breasts started shrinking; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 39 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 3(booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, for COVID-19 immunization, reaction(s): "After the first shot, she noticed her breasts were growing back"; Bnt162b2 (DOSE 2), for COVID-19 immunization. The following information was reported: BREAST ATROPHY (non-serious), outcome "unknown", described as "after the third dose, she states that her breasts started shrinking". Therapeutic measures were not taken as a result of breast atrophy.  The lot number for bnt162b2 was not provided and will be requested during follow up.
A "Bells-Palsy"-like symptoms: numbness, tingling, ringing in ears, taste sensation lost, headache/neck pain stiffness. Dropping on right side of face.
Five to ten minutes after receiving vaccine, she fainted in lobby, hit back of head on tile floor. I ran out to lobby to see her on floor. She appeared to have a small reflexive arching of her body for 5-10 seconds. No history of seizures. She regained consciousness and responded to questions. We called the medics, came within 5 minutes, transported to ER. She had no breakfast.
Headache, nausea, chills, fatigue  Onset 5 days post dosing Resolved within 36 hours
This spontaneous report was received from a pharmacist referring to a 63 years old female patient. The patient's medical history, concurrent conditions, drug reactions and allergies were not reported. On 13-SEP-2016, the patient was vaccinated with ZOSTAVAX injection, 1 DF, subcutaneously (dose, lot number and expiration date were not provided). There were no concomitant medications provided. On 13-SEP-2016, reported as immediately after vaccination with ZOSTAVAX the patient developed 1  hive. The patient sought medical attention for evaluation of the hive and no product quality complain was involved. The outcome of urticaria was reported as not recovered. Additional information has been requested.
Received a vaccine that underwent a temperature excursion; No adverse event; Received a vaccine that underwent a temperature excursion; This spontaneous case was reported by a medical assistant and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Received a vaccine that underwent a temperature excursion), POOR QUALITY PRODUCT ADMINISTERED (Received a vaccine that underwent a temperature excursion) and NO ADVERSE EVENT (No adverse event) in an 18-month-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AS1412B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 15-Aug-2022, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Aug-2022, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Received a vaccine that underwent a temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Received a vaccine that underwent a temperature excursion) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Received a vaccine that underwent a temperature excursion), POOR QUALITY PRODUCT ADMINISTERED (Received a vaccine that underwent a temperature excursion) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT TEMPERATURE EXCURSION ISSUE (Received a vaccine that underwent a temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Received a vaccine that underwent a temperature excursion).    The weight of the patient was reported as 22 with unclear unit and 14 oz.  No concomitant medications were reported.  The patient was administered vaccine on 15-Aug-2022, and the location reported was LQ (unspecified).  The reporter stated that the vaccine underwent one temperature excursion one in the freezer and one in the refrigerator. Some vaccines were stored in the freezer and other vials in the refrigerator. The excursion occurred on 07-Aug-2022 and was picked up by state review of the temperature data logger 2 weeks later after the excursion. Total 38 patients received this.  Reportedly, the vial was stored in refrigerated condition at the time of the excursion. The lot number affected was AS1412B and expiration date was 10-Feb-2023. The maximum or minimum temperatures reached was positive 14 degrees Celsius and the excursion duration was 3 hours and 5 minutes. The vial was moved from freezer to refrigerator on 08-Aug-2022. The vials were currently returned to the freezer or refrigerator or maintained at room temperature administered and discarded. The proposed desired used by date was 18-Aug-2022.  No side effects were reported by the patient.  No treatment information was provided by the reporter.
Moderna COVID- 19 Vaccine EUA Date of vaccine 1/11/2021 Moderna Lot # Moderna US, INC Lot 012L20A Expiring 07/06/2021 ; Immunization Admin Covid-19  Dosage 1st Dose Moderna (Z23) Left deltoid site Last night patient noticed a rash on vaccinated arm, red, tender, itchy and warm to the touch. No swelling . Topical Benadryl and Hydrocortisone cream given. Will follow up in clinic next week if no improvement
My son began seizing and was having a hard time breathing during the seizure it lasted about one minute. Then it happened again about five minutes later. I called his doctor and the doctor on call called me back. His name was Dr.  He told me that it must have been reflux. I told him it was not reflux it was a seizure I know what I saw. I asked him if it could have been the vaccine and he insisted that it was not.  My son also became extremely constipated and did not have a bowel movement for about two weeks prior to the vaccines.
Systemic: Lymph Node Swelling-Severe, Additional Details: Lymph node in armpit swelled significantly and extended into breast.
p/1st dose of DTP vax on 2DEC92 pt exp 5-6 hrs of non-stop crying w/no temp;
At 4 days post vaccine lymph nodes in left axilla became swollen and painful which led eventually to both sides, fatigue,  headache, at 7 days injection site became red swollen and itchy
Fever; This case was reported by a pharmacist via call center representative and described the occurrence of fever in a 58-year-old female patient who received Herpes zoster (Shingrix) (batch number 7457P, expiry date 2nd June 2021) for prophylaxis.   On 26th June 2019, the patient received the 2nd dose of Shingrix. On 27th June 2019, 1 days after receiving Shingrix, the patient experienced fever. On an unknown date, the outcome of the fever was unknown.   It was unknown if the reporter considered the fever to be related to Shingrix.  Additional information received were as follows: The pharmacist reported that the patient's body temperature was recorded as 101.0 degree F. No additional details were provided at the time of the call. The reporter consented to follow up.
Severe body aches, joint pain, chills, fever Mild nausea vomiting and abdominal pain
NO adverse event occurred.  We are reporting due to the fact that the patient was 16 years of age and the vaccine has an 18 years of age requirement.   Patient has had no symptoms.  Is patient considered fully vaccinated at 2 weeks like adults 18 years of age or older? Patients parent would like to know as well.
congestion, difficulty breathing, wheezing, tired, not very hungry, some coughing, chills, SOB. starting 10/4/21. Patient lives with daughter who recently tested positive. Patient had 3rd Pfizer booster on 10/1/21. Lot # for all vaccines are NOT available, done at another location.
Rash on the arm near the injection site, last up to 5 days or more.
patient reports to getting a headache a few hours after administration followed by extreme fatigue and then 48 hours of nausea and vomiting.
Patient presented to clinic to show possible flu vaccine reaction on her left arm. Vaccine was given 9/12/13.  raised, red, hot, itchy rash appeared in large localized area between deltoid and elbow with irregular shape/edges.  No other symptoms of SOB, oral swelling, etc.  Symptoms appeared 9/13/23.  . Patient reported that she has had similar responses to soy, which then developed into anaphylaxis upon subsequent exposure to soy.,  There are some other immunity issues patient has been consulting physician about.  Patient advised to seek attention of her primary care physician for evaluation.  Patient advised that VAERS report will be submitted on her behalf.  Patient  agreed.
4 hours after shots, pt developed 103-104 degrees F fever. Then had a generalized seizure lasting 20-30 seconds. Call 911, then was taken to ER in stable condition. Dx'ed with febrile seizure. No URI symptoms, had no more fever.
Pt. noticed redness, itching, and swelling at the injection site was noticed by patient on 10/01/2017. Pt. has not had difficulty breathing or swallowing. Pt. also has no cough or wheezing. Pt. was advised to use TYLENOL/MOTRIN, ice, and rest. Pt. informed that provider will report her adverse event to VAERS. Pt. will also follow up with any new or worsening Sx.
This case was reported by a pharmacist via call center representative and described the occurrence of sinus infection in a 60-year-old female patient who received SHINGRIX (batch number 9XC39, expiry date 30th January 2020) for prophylaxis. On 31st January 2018, the patient received the 1st dose of SHINGRIX. In February 2018, 21 days after receiving SHINGRIX, the patient experienced sinus infection. On an unknown date, the outcome of the sinus infection was unknown. It was unknown if the reporter considered the sinus infection to be related to SHINGRIX. Additional details were provided as follows: Three weeks after vaccination, the patient experienced a sinus infection. The healthcare professional was not sure if the sinus infection was associated with the SHINGRIX. The healthcare professional called medical information for efficacy data after only receiving the 1st dose.
Dose was given after expiration date; expired vaccine is stored and then administered; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose was given after expiration date) and PRODUCT STORAGE ERROR (expired vaccine is stored and then administered) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Oct-2021, the patient experienced PRODUCT STORAGE ERROR (expired vaccine is stored and then administered). On 25-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose was given after expiration date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose was given after expiration date) and PRODUCT STORAGE ERROR (expired vaccine is stored and then administered) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  It was reported that patient had not experienced any adverse event and No Temp excursion was happened to the suspect vaccine.  The product was placed in refrigerator on 18-Oct-2021.   This case was linked to MOD-2022-491837 (Patient Link).
About an hour after the shot, I had a tightening of the chest. I had a little difficulty breathing. I became extremely fatigued. I had a very slight mild headache. After about 2 hours I could breath normally again. After about 4 hours everything was back to normal except for the extreme fatigue that lasted for 7 days.  My premature heart beat has begun to become more frequent after receiving the vaccine. The fatigue never really went away.